GcMaf has been trialled

Around 90 GcMaf research papers have been published in highly respected mainstream journals, which include The Journal of Cellular and Molecular Medicine, the Journal of Oncoimmunology, Journal of Anticancer Research, Journal of Neuroinflammation, Journal of Cancer Immunology & Immunotherapy, Treatment Strategies for Oncology Journal Cambridge, Journal of Translational Oncology, International Journal of Cancer, Journal of Immunology & Cell Biology and the Journal of the National Cancer Institute, Oxford.

And 64 of the 90 scientific papers are republished on the US Government's National Library of Medicine. They are linked from www.GcMaf.eu.

These are among the most prestigious scientific publications on Earth, but it seems Deputy Hadley flatly refuses to read them. If he did, he would know they are not all laboratory work, but they include clinical results from patients.

He states some of the cures have people taking other medications at the same time. No, our protocols are very strict and we do not allow this.

He states we can't know when people are cured. But it starts with HSSD giving patients a report stating they are, for example, terminal stage four cancer and telling them they are going to die. They come to us, take GcMaf, then get hospital scans a year later which prove they are cancer-free. That's how we know.

Both deputies Hadley and Kevin Stewart have been taken in by Cancer Research UK, which in our view raises money to research a cure for cancer when it was found 24 years ago. They rubbish GcMaf on their website, stating there is only one scientist involved when there are 180.

Professor Marco Ruggiero's views on Aids are shared by two Nobel Laureates. The HIV/chemotherapy industry asked his university to withdraw his professorship because his accurate research papers were costing them profits.

The University of Florence backed the professor to the hilt and flatly refused.

So far, not one Guernsey doctor has dared to break ranks and listen to Professor Marco Ruggiero MD, one of the world's top experts on immunology and oncology, even though doctors are allowed to prescribe GcMaf under the GMC Prescription Guidelines 31 January 2013 paragraph 68.

Deputy Hadley complains about a lack of clinical trials. The medical world is a very tightly closed shop. The FDA in the USA wants $900m.spent and 10 years for trials. In the UK, the MHRA wants you to spend about £10m. That's how they keep inexpensive but proven cures out of the system.

He says no pharmaceutical company is allowed to market its products without showing they are safe.

But the human GcMaf protein has already been trialled by the five billion healthy people who have it inside them right now. So thank you, Deputy Hadley, for also trialling GcMaf for us – you have it inside you and you know it has no side-effects.

We've supplied about 8,000 people through 400 doctors and still there are no side-effects.

Compare that with the horrific side-effects of the poison of chemotherapy and the 450 patients over the last three years who have died of cancer in Guernsey after being told chemotherapy was the only option.

Guernsey, as an independent state, could do trials inexpensively and save a fortune at HSSD as people leave their hospital beds and go home, recovered. Then Guernsey could market this billion-pound industry to the world. But this is yet another opportunity our blinkered HSSD and States have been refusing for three years.

Deputy Hadley's final fabrication is that we market at prices that cause hardship. We don't charge in Guernsey, where we are effectively a charity.

In the rest of the world, we are one-fifth the cost of chemotherapy and we give away one-eighth of our overseas production to people who are poor and can't afford it.

We have 25 fabulous results in Guernsey, but Deputy Hadley refuses to meet those people. May we suggest that before he writes yet another letter from a position of apparently complete ignorance on this subject he comes and meets us, meets our participants and reads some research papers? He will be very welcome.

DAVID NOAKES,

dn@gcmaf.eu.